Patients with acute or chronic graft-versus-host disease (GVHD) have several unmet needs, including later-line therapies. Novel agents and other research emerges as well. For the frontline setting, corticosteroids remains the standard of care, firs-line treatment for GVHD. Unfortunately, not all patients respond favorably and some become resistant. Hence, for these patients, physicians may administer JAK1/2 inhibitor ruxolitinib (Jakafi). Upon failure of this treatment, patients begin to run out of options and hence, the world of research becomes imminent. There is no approved “third-line option,” reports the medical director of the Stem Cell Transplant Program with Dana-Farber Cancer Institute.
Graft Versus Host Disease (GVHD)
Characterized by inflammation in various organs, with the specialty of epithelial cell apoptosis and crypt drop out, the GvHD syndrome is commonly associated with stem cell transplants such as those that occur with bone marrow transplants. White blood cells of the donor’s immune system, which remain within the donated tissue (the graft), recognize the recipient (the host) as foreign (non-self). The white blood cells present within the transplanted tis...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).